How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
| Autor: | Ephraim J. Fuchs, Xiao-Jun Huang, Ying-Jun Chang, Leo Luznik |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
medicine.medical_treatment T-Lymphocytes Graft vs Host Disease Histocompatibility Testing Hematopoietic stem cell transplantation Review 0302 clinical medicine immune system diseases HLA Antigens hemic and lymphatic diseases Unmanipulated haploidentical stem cell transplantation Outcome Assessment Health Care Hematology biology Hematopoietic Stem Cell Transplantation lcsh:Diseases of the blood and blood-forming organs lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tissue Donors 3. Good health Donor-specific anti-human leukocyte antigen antibody surgical procedures operative Oncology 030220 oncology & carcinogenesis Hematologic Neoplasms Antibody Donor medicine.drug medicine.medical_specialty endocrine system Cyclophosphamide Human leukocyte antigen lcsh:RC254-282 Donor Selection 03 medical and health sciences Age Antigen Internal medicine medicine Humans Molecular Biology Donor selection lcsh:RC633-647.5 Natural killer alloreactivity Non-inherited maternal antigen mismatch Immunology biology.protein 030215 immunology |
| Zdroj: | Journal of Hematology & Oncology Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-12 (2016) |
| ISSN: | 1756-8722 |
| Popis: | In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can significantly impact the incidences of acute and chronic graft-versus-host disease, transplant-related mortality, and relapse, in addition to overall survival. In this review, we focused on factors associated with transplant outcomes following unmanipulated haplo-SCT with anti-thymocyte globulin (ATG) or after T-cell-replete haplo-SCT with post-transplantation cyclophosphamide (PT/Cy). We summarized the effects of the primary factors, including donor-specific antibodies against human leukocyte antigens (HLA); donor age and gender; killer immunoglobulin-like receptor-ligand mismatches; and non-inherited maternal antigen mismatches. We also offered some expert recommendations and proposed an algorithm for selecting donors for unmanipulated haplo-SCT with ATG and for T-cell-replete haplo-SCT with PT/Cy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|